Navigation Links
VCU study: Researchers discover a drug combination that shrinks tumors in vivo

RICHMOND, Va. (Sept. 27, 2010) Virginia Commonwealth University School of Medicine and VCU Massey Cancer Center researchers have shown that the impotence drug Viagra, in combination with doxorubicin, a powerful anti-cancer drug, enhances its anti-tumor efficacy in prostate cancer while alleviating the damage to the heart at the same time.

For more than four decades the chemotherapeutic agent doxorubicin has been used to treat a number of human cancers, including that of the prostate. Despite doxorubicin's clinical efficacy for cancer treatment, its use is associated with irreversible heart damage, often presenting several years after treatment stops. Researchers have been working over the past 15 years to find an optimal therapeutic intervention for protecting the heart against the cytotoxicity associated with doxorubicin.

In the study published online the week of Sept. 27 in the Early Edition of the journal Proceedings of the National Academy of Sciences, researchers using a variety of powerful in vitro and in vivo approaches, have shown that a combination of Viagra, generically known as sildenafil, and doxorubcin significantly enhances the generation of reactive oxygen species that trigger cell death, or apoptosis, in prostate cancer cells. They also observed that the combination did not harm the normal, healthy prostate epithelial cells.

"We believe sildenafil could be an excellent candidate for incorporation into cancer treatment protocols with the potential of enhancing the anti-tumor efficacy, while protecting the heart against both short term and long term damage from doxorubicin," said principal investigator Rakesh C. Kukreja, Ph.D., scientific director of the VCU Pauley Heart Center and the Eric Lipman professor in cardiology in the VCU School of Medicine, and Anindita Das, Ph.D., assistant professor in the Department of Internal Medicine the VCU School of Medicine.

Kukreja is excited about the potential translational impact of this work. "My team and I are hoping to move the research forward to a clinical trial and plans are under way to do so," he said. The clinical trial would evaluate the effectiveness of the drug combination in cancer patients.

Kukreja's laboratory is one of the first to explore the area of preconditioning. This preconditioning effect was modeled in his lab by "pretreating" mice with doses of sildenafil which also increases therapeutic levels of nitric oxide in the heart.

A preconditioned or pretreated heart has an improved ability to produce nitric oxide and directly improves a patient's outcome following a heart attack. Generally, damage following a heart attack is related to an inability to recover from lack of oxygen.


Contact: Sathya Achia Abraham
Virginia Commonwealth University

Related medicine news :

1. Study: Choice between stroke-prevention procedures influenced by patient age
2. UNC study: Obese 3-year-olds show early warning signs for future heart disease
3. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
4. Henry Ford Hospital study: Shoulder function not fully restored after surgery
5. Study: Federal funds support health depts., but leadership is key
6. Study: Kidney disease a big risk for younger, low-income minorities
7. Study: Mechanomyography to be accurate in detecting nerves during minimally invasive spine surgery
8. Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids
9. Study: Child health may suffer in strong economy
10. Study: Social influence playing role in surging autism diagnoses
11. Children's Rights Group Agrees with New Study: Infant Circumcision Causes 100 Deaths Each Year in US
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... ... , ... Jobs in hospital medical laboratories and in the imaging field lead ... Aureus Medical Group . These fields, as well as travel nursing, ... healthcare jobs through the company’s website, , The leading healthcare staffing ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
(Date:11/26/2015)... UTRECHT, the Netherlands , November 26, 2015 /PRNewswire/ ...   A new combination approach blends immunotherapy ... --> A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with ... the Netherlands has found that immunotherapy ...
Breaking Medicine Technology: